Daiichi Sankyo Company, Limited (TYO:4568)
Japan · Delayed Price · Currency is JPY | Market Cap | 6.90T |
| Revenue (ttm) | 1.92T |
| Net Income (ttm) | 295.87B |
| Shares Out | 1.85B |
| EPS (ttm) | 157.12 |
| PE Ratio | 23.73 |
| Forward PE | 19.19 |
| Dividend | 78.00 (2.14%) |
| Ex-Dividend Date | Sep 29, 2025 |
| Volume | 7,440,900 |
| Average Volume | 6,651,235 |
| Open | 3,640.00 |
| Previous Close | 3,639.00 |
| Day's Range | 3,627.00 - 3,755.00 |
| 52-Week Range | 3,036.00 - 5,086.00 |
| Beta | 0.25 |
| RSI | 60.81 |
| Earnings Date | Oct 31, 2025 |
About Daiichi Sankyo Company
Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, North America, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule that targets colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3 harboring an internal tandem duplication mutation; Vanflyta, a FLT3 inhi... [Read more]
Financial Performance
In 2024, Daiichi Sankyo Company's revenue was 1.89 trillion, an increase of 17.77% compared to the previous year's 1.60 trillion. Earnings were 295.76 billion, an increase of 47.34%.
Financial StatementsNews
Daiichi Sankyo Establishes Third Research Institute in San Diego
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) has established Daiichi Sankyo Research Institute in San Diego, representing the third research institute established outside o...
Daiichi Sankyo Company, Limited (DSKYF) Q2 2024 Earnings Call Transcript
AstraZeneca (AZN) and Daiichi Sankyo's Enhertu Advances in FDA Review
AstraZeneca (AZN) and Daiichi Sankyo's Enhertu Advances in FDA Review
Shares of Asian drugmakers drop after Trump threatens tariffs
Shares of Asian drugmakers mostly fell on Friday after U.S. President Donald Trump threatened 100% tariffs on imports of branded pharmaceuticals from October 1, unless their producers had already brok...
AstraZeneca, Daiichi Sankyo under priority review of FDA for breast cancer
Daiichi Sankyo Company, Limited (DSNKY) Discusses On WCLC 2025 Highlights (Transcript)
Daiichi Sankyo Company, Limited (DSNKY) Discusses On WCLC 2025 Highlights (Transcript)
Daiichi Sankyo Company, Limited (OTCPK:DSNKY) Discusses on WCLC 2025 Highlights (Transcript) Company Participants Kentaro Asakura - Corporate Officer, Head of Corporate Communications Deptt, Global Co...
Daiichi Sankyo Company, Limited (DSNKY) Special Call - Slideshow
2025-09-19. The following slide deck was published by Daiichi Sankyo Company, Limited in conjunction with this event.
Immuto Scientific Announces $8M Seed 2 Financing and Daiichi Sankyo Collaboration to Uncover a New Class of Therapeutic Targets with Structural Surfaceomics
MADISON, Wis. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #biotech--Immuto Scientific Announces Financing and Daiichi Sankyo Collaboration to Uncover a New Class of Therapeutic Targets with Structural Surfa...
Daiichi Sankyo, Merck Say Raludotatug Deruxtecan Granted Breakthrough Therapy Designation
(RTTNews) - Daiichi Sankyo Company Limited (DSKYF) and Merck & Co Inc. (MRK) said on Monday that the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation for their ralu...
10 stocks to consider if you want alternatives to the expensive S&P 500
Stocks in developed economies outside the U.S. tend to trade at lower valuations. Some of the companies are expected to expand their businesses rapidly over the next two years.
Merck (MRK) and Daiichi Sankyo's Ifinatamab Deruxtecan Shows Promise in Lung Cancer Trial
Merck (MRK) and Daiichi Sankyo's Ifinatamab Deruxtecan Shows Promise in Lung Cancer Trial
Daiichi Sankyo Announces the Development of a Fixed-Triple Combination Lipid-Lowering Tablet to Address Persistent Gaps in the Management of Elevated LDL-C
MUNICH, Germany--(BUSINESS WIRE)--Daiichi Sankyo Europe is pleased to announce the development of a fixed-triple oral combination lipid-lowering tablet of bempedoic acid, ezetimibe, and different dose...
Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C
MUNICH, Germany--(BUSINESS WIRE)--Daiichi Sankyo Europe is pleased to announce the initiation of the development of new oral triple combination tablets in Europe of bempedoic acid, ezetimibe, and diff...
Daiichi Sankyo Presents New Data in Small Cell Lung Cancer and Updates Across ADC Portfolio Highlighting Progress in Creating New Standards of Care for Patients with Lung Cancer at WCLC
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) will present new clinical research across its DXd antibody drug conjugate (ADC) portfolio in lung cancer at the IASLC 2025 Worl...
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...
Daiichi Sankyo Company, Limited (DSKYF) Q1 FY2025 Earnings Call Transcript
President Trump demands drugmakers slash prices within 60 days
CNBC's Joe Kernen reports on the latest news.
Daiichi Sankyo has inventory buffer, will expand production capacity in Ohio to mitigate US tariffs - CFO
Daichii Sankyo's CFO Koji Ogawa tells CNBC's Squawk Box Asia what the pharma company is doing to mitigate the effects of U.S. tariffs, including optimizing its supply chain and expanding its productio...
Daiichi Sankyo reports Q1 results
AstraZeneca, Daiichi Sankyo get U.S. breakthrough therapy status for Enhertu
ENHERTU® Plus Pertuzumab Granted Breakthrough Therapy Designation in the U.S. as First-Line Therapy for Patients with HER2 Positive Metastatic Breast Cancer
Ninth Breakthrough Therapy Designation for Daiichi Sankyo and AstraZeneca's ENHERTU with the latest based on DESTINY-Breast09 phase 3 trial results Thirteenth Breakthrough Therapy Designation granted ...
Daiichi Sankyo, AstraZeneca gets U.S. approval for Datroway
DATROWAY® Approved in the U.S. as First TROP2 Directed Therapy for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
Based on TROPION-Lung05 phase 2 trial results and supported by data from the TROPION-Lung01 phase 3 trial Second U.S. approval for Daiichi Sankyo and AstraZeneca's DATROWAY in less than six months DAT...
Targeted cancer drugs may replace chemo for some patients and drugmakers say they're getting closer
Companies like AstraZeneca, Daiichi Sankyo, Pfizer and Merck are learning from previous setbacks in the ADC space to improve their efficacy and safety.